Genmab Earnings Reports

Genmab delivered robust Q2 2025 results with 19% year-over-year revenue growth. The performance was fueled by strong royalty revenues from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY. Despite higher costs, operating profit and net income both rose significantly, reflecting effective commercialization strategies and pipeline expansion.

Genmab delivered solid Q4 2024 results with revenue reaching DKK 21,526 million, an increase of 31% year-over-year. Net profit surged to DKK 7,844 million, supported by strong DARZALEX and Kesimpta royalties. Operating profit improved to DKK 6,703 million, while cash and cash equivalents stood at DKK 9,858 million.